Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06554626
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of PD5K3 in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06527781
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangshu, China
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT06376721
- Locations
- 🇨🇳
Liang Wang, Beijing, Beijing, China
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: Asparaginase Erwinia chrysanthemiProcedure: Bone Marrow AspirationProcedure: Computed TomographyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: PrednisoloneDrug: DexamethasoneDrug: PrednisoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyDrug: LeucovorinProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 171
- Registration Number
- NCT06317662
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
Phase 2
Withdrawn
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: Calaspargase PegolProcedure: Computed TomographyDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: Lumbar PunctureDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanBiological: NavitoclaxDrug: PegaspargaseDrug: NelarabineProcedure: Positron Emission TomographyDrug: ThioguanineProcedure: X-Ray ImagingDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT06210750
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 3
Not yet recruiting
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: DaunorubicinDrug: DoxorubicinProcedure: EchocardiographyDrug: LeucovorinDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: PrednisoloneDrug: PrednisoneDrug: VincristineRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 680
- Registration Number
- NCT06124157
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 180
- Registration Number
- NCT05959720
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05700448
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 100
- Registration Number
- NCT05660473
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 440
- Registration Number
- NCT05602194
- Locations
- 🇺🇸
Miami Cancer Institute, Miami, Florida, United States
🇺🇸Ascension Borgess Hospital, Kalamazoo, Michigan, United States
🇺🇸Presbyterian Hospital, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath